What is Curesponse?
Curesponse is an Israeli-based company operating in the cancer precision medicine sector. Its core offering is the cResponse platform, designed to accurately and efficiently predict a patient's response to various cancer treatments. This predictive capability is crucial for optimizing therapeutic strategies and improving patient outcomes in oncology.
How much funding has Curesponse raised?
Curesponse has raised a total of $14M across 2 funding rounds:
Series A
$6M
Unspecified
$8M
Series A (2020): $6M with participation from aMoon and NCL Technology Ventures Ltd
Unspecified (2021): $8M, investors not publicly disclosed
Key Investors in Curesponse
NCL Technology Ventures Ltd
NCL Technology Ventures Ltd is an investor that participated in Curesponse's Series A funding round. Further details on their investment focus are not publicly available.
What's next for Curesponse?
With substantial enterprise-level backing and a recent strategic investment, Curesponse is poised for significant expansion and further development of its predictive oncology platform. The company's focus on accurate treatment response prediction aligns with the growing demand for personalized medicine in cancer care. Future endeavors will likely involve scaling operations, enhancing the cResponse platform's capabilities, and forging strategic partnerships within the healthcare and pharmaceutical industries to broaden its market reach and impact.
See full Curesponse company page
